T-DXd and Dato-DXd are now approved treatments in Japan for patients with breast cancer.
|Articles|July 1, 2006
Oncology NEWS International
- Oncology NEWS International Vol 15 No 7
- Volume 15
- Issue 7
Genentech Seeks Expanded Use of Avastin in Breast Cancer
Genentech Seeks Expanded Use of Avastin in Breast Cancer
Advertisement
SAN FRANCISCO, CalifGenentech has submitted an application to the FDA for expanded use of bevacizumab (Avastin) in combination with taxane chemotherapy for treatment of chemotherapy-naïve recurrent or metastatic breast cancer. Phase III data showed that patients who received bevacizumab in combination with paclitaxel had a 52% reduction in risk of disease progression or death, compared to those who received paclitaxel alone.
Articles in this issue
about 20 years ago
High-Quality Screening Colonoscopy Priority for GI Docsabout 20 years ago
Denosumab Suppresses Bone Resorption in Breast Ca Metsabout 20 years ago
FDA Approves Priority Review of Merck's Zolinza (Vorinostat)about 20 years ago
FDA Approves Revlimid for Myeloma Rxabout 20 years ago
Real-Time RT Planning, Delivery in the Bronxabout 20 years ago
Phase III Trial of Enzastaurin for NHL Patients Initiatedabout 20 years ago
Racial Disparities in Prostate Ca Recurrenceabout 20 years ago
HNPCC Pts May Reject Prophylactic Subtotal ColectomyAdvertisement
Related to this article
Data from the phase 3 EMBER-3 trial support the full approval of imlunestrant plus abemaciclib in this breast cancer population.
NICE recommended trastuzumab deruxtecan for reimbursement in England for HER2-low metastatic breast cancer, backed by DESTINY-Breast04 data.
Trastuzumab botidotin more than doubled median PFS vs trastuzumab emtansine in HER2-positive advanced breast cancer in the phase 3 KL166-III-06 trial.
Camizestrant/palbociclib did not significantly improve PFS vs anastrozole/palbociclib in first-line ER+/HER2– breast cancer in the phase 3 SERENA-4 trial.
Erica L. Mayer, MD, MPH, discussed the practical questions clinicians must answer as the SERENA-6 early-switch approach with camizestrant enters practice.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA MCGP Panel Votes in Favor of the Galleri Multicancer Early Detection Test
2
Belzutifan Combo Receives FDA Approval in Advanced Clear Cell RCC
3
FDA Grants Approval to Lirafugratinib for Advanced Cholangiocarcinoma with FGFR2 Alteration
4
Approaching Cardiovascular Risk in Prostate Cancer Hormonal Therapy
5